• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form DEFA14A filed by Artivion Inc.

    4/1/25 4:49:56 PM ET
    $AORT
    Medical/Dental Instruments
    Health Care
    Get the next $AORT alert in real time by email
    DEFA14A 1 artiv-defa14a_051325.htm ADDITIONAL DEFINITIVE PROXY MATERIALS
     

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, D.C. 20549

    SCHEDULE 14A INFORMATION

    Proxy Statement Pursuant to Section 14(a) of the
    Securities Exchange Act of 1934
    (Amendment
    No. )

    Filed by the Registrant ☒

    Filed by a Party other than the Registrant ☐

    Check the appropriate box:

    ☐Preliminary Proxy Statement

    ☐Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))

    ☐Definitive Proxy Statement

    ☒Definitive Additional Materials

    ☐Soliciting Material under §240.14a-12

    ARTIVION, INC.

    (Name of Registrant as Specified In Its Charter)

    Payment of Filing Fee (Check all boxes that apply):

    ☒No fee required.

    ☐Fee paid previously with preliminary materials.

    ☐Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11.

     

    ​

    Important Notice of Availability of Proxy Materials for the Stockholder Meeting of

     

    To Be Held On:

    May 13, 2025 at 9:00 a.m. EDT

    Meeting live via the Internet – please visit https://web.lumiconnect.com/295739807 (password: artivion2025)

     

      COMPANY NUMBER  
      ACCOUNT NUMBER  
      CONTROL NUMBER  

    This communication presents only an overview of the more complete proxy materials that are available to you on the Internet. We encourage you to access and review all of the important information contained in the proxy materials before voting.

    If you want to receive a paper or e-mail copy of the proxy materials you must request one. There is no charge to you for requesting a copy. To facilitate timely delivery please make the request as instructed below before May 1, 2025.

    Please visit http://www.astproxyportal.com/ast/01609, where the following materials are available for view:

      ● Notice of Annual Meeting of Stockholders
      ● Proxy Statement
      ● Form of Electronic Proxy Card
      ● Annual Report on Form 10-K
       
    TO REQUEST MATERIAL:

    TELEPHONE: 888-Proxy-NA (888-776-9962) or 201-299-6210 (for international callers)

    E-MAIL: [email protected]

    WEBSITE: https://us.astfinancial.com/OnlineProxyVoting/ProxyVoting/RequestMaterials

    TO VOTE:
                            
    ONLINE: To access your online proxy card, please visit www.voteproxy.com and follow the on-screen instructions or scan the QR code with your smartphone. You may enter your voting instructions at www.voteproxy.com up until 11:59 PM EDT the day before the meeting date.
    VIRTUALLY AT THE MEETING: The company will be hosting the meeting live via the Internet this year. To attend the meeting via the Internet, please visit https://web.lumiconnect.com/295739807 (password: artivion2025) and be sure to have your control number available.
    TELEPHONE: To vote by telephone, please visit www.voteproxy.com to view the materials and to obtain the toll free number to call.
      MAIL: You may request a card by following the instructions above.

    1. Election of Directors

     

        NOMINEES:

    Thomas F. Ackerman
    Daniel J. Bevevino
    Marna P. Borgstrom
    James W. Bullock
    Jeffrey H. Burbank
    Elizabeth A. Hoff
    J. Patrick Mackin
    Jon W. Salveson
    Anthony B. Semedo

     

    2.       To approve, by non-binding vote, the compensation paid to Artivion’s Named Executive Officers, as disclosed pursuant to Item 402 of Regulation S-K, including the Compensation Discussion and Analysis, compensation tables, and narrative discussion.

     

    3.       To ratify the preliminary approval of Ernst & Young LLP as the independent registered public accounting firm for the company for the fiscal year ending December 31, 2025.

     

    4.       To approve additional funding of 3,570,000 shares for the Amended and Restated Artivion, Inc. 2020 Equity and Cash Incentive Plan.

     

    5.        In their discretion, upon such other matters as may properly come before the meeting.

     

           
           
           
           
           
           
    Please note that you cannot use this notice to vote by mail.  
           
           
           

     

     

    Get the next $AORT alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $AORT

    DatePrice TargetRatingAnalyst
    8/13/2025$38.79Buy → Neutral
    Ladenburg Thalmann
    6/17/2025$35.00Buy
    Canaccord Genuity
    10/23/2024$33.00Mkt Outperform
    JMP Securities
    9/27/2022$32.00 → $28.00Buy
    Lake Street
    8/8/2022$32.00Buy
    Lake Street
    3/3/2022$30.00Buy
    Stifel
    2/18/2022$39.00 → $30.00Buy
    Needham
    More analyst ratings

    $AORT
    SEC Filings

    View All

    SEC Form 144 filed by Artivion Inc.

    144 - ARTIVION, INC. (0000784199) (Subject)

    12/17/25 2:50:54 PM ET
    $AORT
    Medical/Dental Instruments
    Health Care

    SEC Form 10-Q filed by Artivion Inc.

    10-Q - ARTIVION, INC. (0000784199) (Filer)

    11/7/25 11:41:27 AM ET
    $AORT
    Medical/Dental Instruments
    Health Care

    Artivion Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - ARTIVION, INC. (0000784199) (Filer)

    11/6/25 4:09:27 PM ET
    $AORT
    Medical/Dental Instruments
    Health Care

    $AORT
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    May 23, 2023 - FDA Roundup: May 23, 2023

    For Immediate Release: May 23, 2023 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency:  On Monday, the FDA and the Veterans Health Administration announced a new collaboration to jointly develop emergency preparedness and response tools and protocols intended to help increase medical product manufacturing capacity and flexibility, and improve resilie

    5/23/23 4:06:19 PM ET
    $AORT
    Medical/Dental Instruments
    Health Care

    $AORT
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Semedo Anthony B. bought $53,140 worth of shares (2,100 units at $25.30), increasing direct ownership by 4% to 35,659 units (SEC Form 4)

    4 - ARTIVION, INC. (0000784199) (Issuer)

    3/5/25 4:01:01 PM ET
    $AORT
    Medical/Dental Instruments
    Health Care

    $AORT
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Artivion Announces Presentation of Positive New Clinical Data from NEXUS TRIOMPHE and AMDS PERSEVERE Trials at the 62nd Society of Thoracic Surgery Annual Meeting

    1-Year Data from Endospan's NEXUS TRIOMPHE IDE Trial Demonstrate High Patient Survival with Low Morbidity 2-Year Data from the AMDS PERSEVERE IDE Trial Further Demonstrate the Persistent Clinical Benefit of AMDS ATLANTA, Feb. 2, 2026 /PRNewswire/ -- Artivion, Inc. (NYSE:AORT), a leading cardiac and vascular surgery company focused on aortic disease, today announced the presentation of new clinical data from Endospan's NEXUS TRIOMPHE IDE trial and its AMDS PERSEVERE IDE trial at the 62nd Annual Meeting of the Society of Thoracic Surgeons in New Orleans, Louisiana.   The NEXUS T

    2/2/26 8:00:00 AM ET
    $AORT
    Medical/Dental Instruments
    Health Care

    Artivion Announces Release Date and Teleconference Call Details for Fourth Quarter 2025 Financial Results

    ATLANTA, Jan. 29, 2026 /PRNewswire/ -- Artivion, Inc. (NYSE:AORT), a leading cardiac and vascular surgery company focused on aortic disease, announced today that fourth quarter 2025 financial results will be released on Thursday, February 12, 2026, after the market closes. On that day, the Company will hold a teleconference call and live webcast at 4:30 p.m. ET to discuss the results, followed by a question-and-answer session hosted by Pat Mackin, Chairman, President and Chief Executive Officer of Artivion. To listen to the live teleconference, please dial 201-689-8261 a few m

    1/29/26 4:05:00 PM ET
    $AORT
    Medical/Dental Instruments
    Health Care

    Artivion Reports Third Quarter 2025 Financial Results

    Third Quarter Highlights: Achieved revenue of $113.4 million in the third quarter of 2025 versus $95.8 million in the third quarter of 2024, an increase of 18% on a GAAP basis and 16% on a non-GAAP constant currency basisNet income was $6.5 million, or $0.13 per fully diluted share, and non-GAAP net income was $7.9 million, or $0.16 per fully diluted share in the third quarter of 2025Adjusted EBITDA increased 39% to $24.6 million in the third quarter of 2025 compared to $17.7 million in the third quarter of 2024Enrolled first patient in ARTIZEN U.S. Investigational Device Exemption trial for ArcevoATLANTA, Nov. 6, 2025 /PRNewswire/ -- Artivion, Inc. (NYSE:AORT), a leading cardiac and vascul

    11/6/25 4:05:00 PM ET
    $AORT
    Medical/Dental Instruments
    Health Care

    $AORT
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Stanton Marshall S. was granted 850 shares, increasing direct ownership by 2% to 45,603 units (SEC Form 5)

    5 - ARTIVION, INC. (0000784199) (Issuer)

    1/28/26 3:53:37 PM ET
    $AORT
    Medical/Dental Instruments
    Health Care

    Davis John E was granted 874 shares, increasing direct ownership by 0.45% to 194,716 units (SEC Form 5)

    5 - ARTIVION, INC. (0000784199) (Issuer)

    1/28/26 3:50:54 PM ET
    $AORT
    Medical/Dental Instruments
    Health Care

    Holloway Jean F was granted 857 shares, increasing direct ownership by 0.55% to 156,950 units (SEC Form 5)

    5 - ARTIVION, INC. (0000784199) (Issuer)

    1/28/26 3:47:08 PM ET
    $AORT
    Medical/Dental Instruments
    Health Care

    $AORT
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Artivion downgraded by Ladenburg Thalmann with a new price target

    Ladenburg Thalmann downgraded Artivion from Buy to Neutral and set a new price target of $38.80

    8/13/25 8:00:59 AM ET
    $AORT
    Medical/Dental Instruments
    Health Care

    Canaccord Genuity initiated coverage on Artivion with a new price target

    Canaccord Genuity initiated coverage of Artivion with a rating of Buy and set a new price target of $35.00

    6/17/25 7:48:51 AM ET
    $AORT
    Medical/Dental Instruments
    Health Care

    JMP Securities initiated coverage on Artivion with a new price target

    JMP Securities initiated coverage of Artivion with a rating of Mkt Outperform and set a new price target of $33.00

    10/23/24 6:17:27 AM ET
    $AORT
    Medical/Dental Instruments
    Health Care

    $AORT
    Leadership Updates

    Live Leadership Updates

    View All

    Artivion Appoints Lance A. Berry as Executive Vice President, Chief Financial Officer; Announces Retirement of D. Ashley Lee, Chief Financial Officer

    Reaffirms Financial Guidance Provided on November 2, 2023 ATLANTA, Dec. 6, 2023 /PRNewswire/ -- Artivion, Inc. (NYSE:AORT), a leading cardiac and vascular surgery company focused on aortic disease today announced the appointment of Lance A. Berry as the Company's Chief Financial Officer, effective as of December 4, 2023. In this role, Mr. Berry joins Artivion's executive leadership team and replaces Mr. D. Ashley Lee, who will retire at the end of the year after a successful and long tenure with the Company and a distinguished career in the medical device industry. Artivion also reaffirmed its full-year 2023 financial guidance that was provided on November 2, 2023.

    12/6/23 4:15:00 PM ET
    $AORT
    Medical/Dental Instruments
    Health Care

    Sequana Medical announces results of Special General Meeting of Shareholders

    PRESS RELEASEREGULATED INFORMATION26 June 2023, 06:00 pm CEST Dr. Kenneth Macleod appointed as non-executive director Ghent, Belgium – 26 June 2023 – Sequana Medical NV (Euronext Brussels: SEQUA) (the "Company" or "Sequana Medical"), a pioneer in the treatment of fluid overload in liver disease, heart failure and cancer, today announces that all proposed resolutions submitted to the Special General Meeting of Shareholders were approved at the meeting held today at 09:00 am CEST. The items on the agenda of the meeting included the appointment of Dr. Kenneth Macleod as non-executive director of the Company and the approval in accordance with Article 7:151 of the Belgian Companies and Asso

    6/26/23 12:00:00 PM ET
    $AORT
    $PHAR
    Medical/Dental Instruments
    Health Care
    Biotechnology: Pharmaceutical Preparations

    Elizabeth Hoff Joins Artivion Board of Directors

    ATLANTA, Sept. 29, 2022 /PRNewswire/ -- Artivion, Inc. (NYSE:AORT), a leading cardiac and vascular surgery company focused on aortic disease, today announced the appointment of Elizabeth A. Hoff to its Board of Directors effective October 1, 2022. "We are excited to welcome Elizabeth to our Board of Directors," said Pat Mackin, Chairman, President, and Chief Executive Officer. "Elizabeth brings a wealth of knowledge in the medical device industry demonstrated by her tenure in the aortic space leading teams focused on the development and commercial launch of innovative healthca

    9/29/22 4:10:00 PM ET
    $AORT
    Medical/Dental Instruments
    Health Care

    $AORT
    Financials

    Live finance-specific insights

    View All

    Artivion Reports Third Quarter 2025 Financial Results

    Third Quarter Highlights: Achieved revenue of $113.4 million in the third quarter of 2025 versus $95.8 million in the third quarter of 2024, an increase of 18% on a GAAP basis and 16% on a non-GAAP constant currency basisNet income was $6.5 million, or $0.13 per fully diluted share, and non-GAAP net income was $7.9 million, or $0.16 per fully diluted share in the third quarter of 2025Adjusted EBITDA increased 39% to $24.6 million in the third quarter of 2025 compared to $17.7 million in the third quarter of 2024Enrolled first patient in ARTIZEN U.S. Investigational Device Exemption trial for ArcevoATLANTA, Nov. 6, 2025 /PRNewswire/ -- Artivion, Inc. (NYSE:AORT), a leading cardiac and vascul

    11/6/25 4:05:00 PM ET
    $AORT
    Medical/Dental Instruments
    Health Care

    Artivion Reports Second Quarter 2025 Financial Results

    Second Quarter Highlights: Achieved revenue of $113.0 million in the second quarter of 2025 versus $98.0 million in the second quarter of 2024, an increase of 15% on a GAAP basis and 14% on a non-GAAP constant currency basisNet income was $1.3 million, or $0.03 per fully diluted share and non-GAAP net income was $10.7 million, or $0.24 per fully diluted share in the second quarter of 2025Adjusted EBITDA increased 33% to $24.8 million in the second quarter of 2025 compared to $18.6 million in the second quarter of 2024Exchanged $99.5 million in principal amount of outstanding convertible senior notes due July 1, 2025 for common stock, resulting in the effective retirement of previously issued

    8/7/25 4:05:00 PM ET
    $AORT
    Medical/Dental Instruments
    Health Care

    Artivion Reports First Quarter 2025 Financial Results

    First Quarter Highlights: Achieved revenue of $99.0 million in the first quarter of 2025 versus $97.4 million in the first quarter of 2024, an increase of 2% on a GAAP basis and 4% on a non-GAAP constant currency basisNet loss was $(0.5) million, or $(0.01) per fully diluted share and non-GAAP net income was $2.5 million, or $0.06 per fully diluted share in the first quarter of 2025Adjusted EBITDA increased 1% to $17.5 million in the first quarter of 2025 compared to $17.3 million in the first quarter of 202430-day data from Endospan's NEXUS TRIOMPHE IDE trial presented at the AATS Annual Meeting demonstrated a 63% reduction in the major adverse event (MAE) rate compared with reference perf

    5/5/25 4:05:00 PM ET
    $AORT
    Medical/Dental Instruments
    Health Care

    $AORT
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Artivion Inc.

    SC 13G/A - ARTIVION, INC. (0000784199) (Subject)

    11/8/24 10:29:29 AM ET
    $AORT
    Medical/Dental Instruments
    Health Care

    SEC Form SC 13G filed by Artivion Inc.

    SC 13G - ARTIVION, INC. (0000784199) (Subject)

    3/11/24 5:45:25 PM ET
    $AORT
    Medical/Dental Instruments
    Health Care

    SEC Form SC 13G/A filed by Artivion Inc. (Amendment)

    SC 13G/A - ARTIVION, INC. (0000784199) (Subject)

    2/14/24 6:18:56 AM ET
    $AORT
    Medical/Dental Instruments
    Health Care